Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425820 | 0.91 | MRGPRX4 (0.47) | CASRL3MBTL1ALDH1A1GAASIGMAR1 | |
| SCHEMBL425298 | 0.90 | L3MBTL1 (0.48) | L3MBTL1KDM4EGAASIGMAR1CASP7 | |
| SCHEMBL430391 | 0.88 | DDR2 (0.42) | L3MBTL1KDM4ESIGMAR1DDR2MEN1 | |
| SCHEMBL425402 | 0.88 | KMO (0.45) | L3MBTL1KDM4ESIGMAR1DDR2MEN1 | |
| SCHEMBL425404 | 0.88 | KMO (0.45) | L3MBTL1KDM4ESIGMAR1DDR2MEN1 | |
| SCHEMBL430389 | 0.88 | DDR2 (0.42) | L3MBTL1KDM4ESIGMAR1DDR2MEN1 | |
| SCHEMBL425345 | 0.87 | DDR2 (0.42) | L3MBTL1ALDH1A1SIGMAR1DDR2CASP7 | |
| SCHEMBL425347 | 0.87 | DDR2 (0.42) | L3MBTL1ALDH1A1SIGMAR1DDR2CASP7 | |
| SCHEMBL426673 | 0.84 | MAPT (0.42) | L3MBTL1KDM4ESIGMAR1DDR2MEN1 | |
| SCHEMBL425814 | 0.84 | SIGMAR1 (0.40) | SIGMAR1DDR2CASP7CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | claimed |
| US-7687498-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-03-30 | — | — | US | claimed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | claimed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100173413-A1 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-7687498-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | CASR 4443/4885NR1H4 738/4885L3MBTL1 4848/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | CASR 2524/4885NR1H4 115/4885L3MBTL1 1129/4885 |
| US-20100173413-A1 | PYRIDINE COMPOUNDS | IL2, IL4, IL6 | CASR 4004/4885NR1H4 179/4885L3MBTL1 4499/4885 |
| US-20050250774-A1 | Pyridine compounds | IL2, IL4, IL6 | CASR 4004/4885NR1H4 179/4885L3MBTL1 4499/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | CASR 3798/4885NR1H4 2303/4885L3MBTL1 3992/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | CASR 2524/4885NR1H4 115/4885L3MBTL1 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.